Inlmducliun: Bu)~rcllorphinc IS an opiate analgcblc uscd in adulls. c l~~l d r c~~ and 111 ~IIC ncwbom.
buprenorphinc i n the pretem newborn. This has not been studied previously.
Subiects: I 2 ventilated. pretem infants (27 -32 weeks geslation).
I n t e r v e n t i o n : Buprenorphinc adminisIralion as a loading dose (3rncgIkg) and continuous infusion (0.72 mcgllglhr) ~e a s u~m e n t s :
Serial blood samples for buprenorphine concentration, blood gases and blood glucose. Heart rate, blood pressure and rcspiralory rate wen: n~easured.
Hcsul(siThcrc were significant (p<0.05) falls i n hcart rate and systolic blood pressure from basclinc values during huprcnorphi~~e infusion. Mean(SD) slcady state buprenorphinc conccnlration was 3.6(1.8) nglml. Mean(SD) clcararlce o f buprcnorphine was 4.3(1.8) ntl/min/kg and lcrnlinal h a l f -l~f e III exccss o f 2 4 I~o u r l . Four infants required an increase i n Ihc buprenorphinc infusiol~ raw and onc ininlit \\,;IS withdrawn bccausc of inadcquatc scdafion. Conclusions ( I ) Buprenorphinc illfusion i n this ;Ige group sltoucd i~~crc;lscd s~c.~dy slalc concentralion, reduced clearance and prolonged h a l f -l~f c c u l~~~~a r c d to older childrcn and adults. (2) B~lprcnorph~nc in thc prc-term ncwborn ;lppcars l o bc saie hut no1 always effcclivc. (3) There is a non-standard rclalior~ship hcla.ccn (he pham;~cological effccl ancl plasma drug cnncentraliol~ which rnakes I~uprenur~,h~r~c inappropriate for use in neonalal intensive care.
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I n i m m a t u r e l a & p r o h l a c t i c LV p r o v i d e s b e t t e r g a s
e x c h a n e t h a n g a s v e n t i y a z i o n (GV). a n d GV (G-1V:n-9) s i n c e b i r t h (J.App1. P h y s i o l . 7 2 : 1 0 2 4 : 1 9 9 2 ) . O x y g e n a t i o n i m p r o v e d a f t e r t h e r a p y i n b o t h r e s c u e g r o u p s , n o t r e a c h i n g G -I 1 1 l e v e l s . I n G -I 1 p a 0 2 d e c r e a s e b y 2.5h, a n d i n G -I r e m a i n e d u n c h a n g e d w h i l e P I P a n d PEEP n e e d t o b e i n c r e a s e d t o v a l u e s a b o v e t h o s e o f G-111. I n b o t h G -I a n d I 1 p u l m o n a r y c o m p l i a n c e s i m i l a r l y i n c r e a s e d a f t e r r e s c u r e a n d c o m p a r e d t o u n t r e a t e d l a m b s b e e n l e s s t h a n i n G-111. L a b e l e d SF was d i s t r i b u t e d w i i h > 6 5 % o f l u n g s e c t i o n s w i t h a n a m o u n t w i t h i n 2 0 % o f mean.
B l e e d i n g t h r o u g h t r a c h e a l t u b e was s e e n i n 5 / 8 l a m b s i n C -I i m m e d ia t e l y a f t e r t r e a t m e n t a n d was n o t s e e n i n o t h e r g r o u p s .
G r o s s a n d m i c r o s c o p i c e x a m i n a t i o n o f l u n g s d e m o n s t r a t e d
e v i d e n c e o f hemmorhage a n d u n e v e n i n f l a t i o n i n a l l g r o u p s b u t C-111. E v e n i n v e r y i m m a t u r e l a m b s b o t h r e s c u e s t r a t e g i e s t r a n s i e n t l y i m p r o v e g a s e r c h a n a n d p u l m o n a r y f u n c t i o n : a l t h o u g h e x p o s u r e o f i m m a t u r e T u n g t o GV a f t c r by Jank JLockcr~'); DepartmQent of I'ed~ntrics, U n i L r s i r y o f y c u v r r r l~c l~r t i r i t * and Deportmcnr of Uiochemlstry, Snpporo Medical Collegc, jirpon". Uroncl~opulmonary dysplaslu (III'D) following respiratory d~s t r r s s s y~~l l r o r~i v ([IDS) has becn corrclntcd wltlt pcrslstcnt surfuctur~t dcliclcrlcy, i~ l l r o l o~~g~~d ncutrophll inllux and a dccrcascd macrophagc response In trnchcai aspIrare contents during the second half of the first week. Thcsc variablca have nut been studied comparing mild (type I ) and severe (type 2) forms of Ui'L). \Ye prospcctlvcly ~rlcnsurcd SI'-A, protcln c t~~~c r r l t r a t i~~n , n c u t r o l l l~~l :~r~< l rrl;t<-r<r-phage counts In 376 tracheal aspirate sarnples o l 105 cortsccut~vcly v c n t~l atcd newborn infants In a longitudinal fashlon. Flfty-eight patients had RDS (group A). 28 hnd pulmonary dlscnses other than RDS (groull I j ) u r~d 19 Itad no lung disease (group C). A t day I, RDS patients had lowcr levels 01 SP-A, protein, ncutrophll and macrophnge counts than Infants o f groups B and C. Among patlcnts wlth RDS, survival without UI'D was associated wlth an increase i n tracheal SP-A concentration, neutrophil and macrophage count bctwccn day I and day 3 t o 5; type I UI'D was associated w l~l~ on incrcasc 111 SP-A w i t l~u u l o ccllulur III~IIIX, t~n d 'poor ~~t~t ( : o t r~c ' (type 2 111' 1) or IIOII- survival at day 28) was assoclatcd with nelther SP-A lncrcasc nor lnflamrnntory response. Our flndings conflrm that a sustained Increase In tracheal surfactant conccnirutlon and rnucropl~ogc courll Is uvsuclutcd wit11 III>S survival wlthout UPD. However, contrary t o current understanding, i t is suggested that cure o f RDS also requires a neutrophil inflammatory response, which Is absent I n type 1 and type 2 UPD patients and nonsurvivors. The latter two also f a l l to produce surfactant. Early treatrncnt w~t h corricosteroids may therefore not be appropriate for thcsc inlants. 
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ASPIRIN VERSUS INDOMETHACINE TREATMENT OF PATENT DUCTUS ARTERIOSUS (PDA) I N THE PRETERM NEONATE WITH RESPIRATORY DISTRESS SYNDROME (RDS). B a r t Van
Indomethacine ( I n d o ) 1s convnonly used f o r treatment o f FDA, i t s main aide a f f e c t 1s r e n a l f a i l u r e .
A s p i r i n (Ash) Is a n a l t e r n a t i v e b u t t h e r e are no c o n t r o l l e d t r i a l s on i t s e f f i c a c y . W e randomly asBigned 75 premature i n f a n t s s u f f e r i n g from RDS (mean GA: 29.6 t 2.5 wks, mean BW: 1295 i 464 g r ) on a r t l f i c l a l v e n t i l a t i o n a t s t a r t o f study (mean : 3.4 day of l i f e ) , t o e l t h s r Indo (3 x 0.2 m g l k g j l 2 h r e ) o r ASA (4 x 15 mg/kg/6 h r s ) .
POP. and degree o f shunting were diaqnosed by echocsrdlo-Doppler a t s t a r t and a f t e r 2 and 4 days. Side e f f e c t s , e a p e c l a l l y d l m i n u t l o n of d l u r e e i s , were c a r e f u l l y recorded.
ResultetPDA cloead i n 35/38 p a t i e n t 8 from the Indo group (93 \ ) and i n 16/37 patient. from the ASA group (43 \ ) (p<0.001).
No reop e n l n g s were obmerved I n b o t h groups. 19 p a t i e n t s needed f u r t h e r treatment w i t h Indo o r murgery (17 I n the ASA group and 2 i n t h e Indo g r o u p ) . No s i d e e f f e c t s were seen i n b o t h groups except f o r a dec r e a s e o f d l u r e s l s I n t h e Indogroup d u r i n g 4 p o s t t r e a t m e n t days l d i f f e r e n c e on 2nd p o s t t r e a t m e n t day: Indo minus 1.06 m l / k g / h v s ASAI p l u s 0.48 m l / k g / h i p<0.01). and dcsa~uralcd (IIB-) In 24 rats Thc rats ucrc dltldcd tnlo 2 groups (Gp) Gpl (12). W1=2n6+l8g (nliSD) rcccl\cl: Al (dor 200 mgkg IP) and was subjcctcd lo I12 hr pcrlcd o l 9 7%02 lolloucd bj I(H)"&, Gg2 (12). Wl-282?JIg (miSD) war subjcctcd lo lhc sanlc 2 pcrtods olF102 bul ut~houl prior Al *Rrsultr: GIII Wtlh adm~n~slral~on of 9 7% 02. C ) m j h a m e morc rcduccd, b) as much as ! MI : ; ol IOI~I l~bllc signal CTLS). UIIII conconlllatll 1, 111 111 U'/ and 11bO and rnr on Ilb-Wlllt ~dt~~tr8~rlraltor or 100% 02. C)laa3 bccanlc nlorc o\ldl/crl \\llll concomltanl r t r la BV and llbO and LII 11, Ilb-G1, 2 Dur~ng Ihc h)po\lc pcrlod (') ~h c clungcs In C)laa3. BV, llbO and Ilb-ucrc slnlllar lo lhor oblalncd In Gpl Howcvcr on rco\)gc~lallon allh 100% 02 Ihc C)laal rcrttaaacd rcduccd dcsptlc lncrcascs In BV and HbO and fall In Ilb-To c\alualc Ihc rolc of IIS and XO III lhcr cbangcs.an addltlonal 6 rats on 100% O2 ucrc lnluscd ullh I HX (dor cnlcul;~lcd lo prot~dc ; I plasma conccnlrallon 30 pWdl) 2 IIX allh Arab~nor (dor 2-4 nll o l 1 6 M Sol ) 3 llX + SO ( I unit) Infurlon of ILX, and XO. wlh or ~inhout arablnor, dld not rcsull In an! chrl~gc ~n C!I.LI] Our rcsuils suggcsl lhal allopur~nol prolcct lhc n~llcchondrlal clcctron-lrasrpan clt.x~n front 0; di~rlng rco\)gcnal~on-rcpcrfus~on lolloa~ng ccrcbral It)po~tc-~scl~cn~~c 11yur) pr&.tbl! b! rc:l\cnitng 0!. r:lll~cr 11 ,I b) ~nhlblllon o l %nnthlnc o\ld;lsc 
